Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 9.95%273.89B | 14.71%178.4B | 18.12%86.56B | 21.99%337.59B | 22.68%249.1B | 22.87%155.53B | 25.01%73.28B | 25.82%276.74B | 27.04%203.05B | 30.22%126.58B |
| Operating income | 9.95%273.89B | 14.71%178.4B | 18.12%86.56B | 21.99%337.59B | 22.68%249.1B | 22.87%155.53B | 25.01%73.28B | 25.82%276.74B | 27.04%203.05B | 30.22%126.58B |
| Cost of sales | -21.68%-185.88B | -20.46%-115.57B | -13.80%-54.14B | -15.74%-207.81B | -16.75%-152.76B | -17.91%-95.94B | -22.63%-47.58B | -13.50%-179.55B | -13.78%-130.85B | -14.77%-81.37B |
| Operating expenses | -21.68%-185.88B | -20.46%-115.57B | -13.80%-54.14B | -15.74%-207.81B | -16.75%-152.76B | -17.91%-95.94B | -22.63%-47.58B | -13.50%-179.55B | -13.78%-130.85B | -14.77%-81.37B |
| Gross profit | -8.65%88.01B | 5.44%62.83B | 26.14%32.41B | 33.54%129.78B | 33.44%96.34B | 31.78%59.59B | 29.67%25.7B | 57.39%97.19B | 61.09%72.2B | 71.83%45.22B |
| Selling expenses | -54.98%-72.34B | -32.55%-38.07B | -11.96%-15.55B | -9.14%-63.98B | -11.42%-46.67B | -14.95%-28.72B | -33.12%-13.89B | -47.48%-58.62B | -44.56%-41.89B | -38.11%-24.99B |
| Administrative expenses | -6.07%-8.26B | -6.26%-5.31B | -14.30%-2.63B | -14.48%-10.73B | -16.78%-7.79B | -20.79%-4.99B | -15.21%-2.3B | 4.09%-9.37B | 8.87%-6.67B | 14.16%-4.13B |
| Research and development expenses | -21.34%-18.97B | -16.37%-12.03B | -15.44%-5.77B | 0.70%-21.05B | 0.90%-15.63B | 1.10%-10.34B | 0.94%-5B | -2.22%-21.2B | -1.80%-15.78B | -3.69%-10.45B |
| Revaluation surplus | 599.86%896.43M | 301.89%1.29B | 255.64%804.82M | -39.84%140.92M | -56.71%128.09M | -337.93%-637.15M | -415.26%-517.12M | 123.12%234.23M | 124.64%295.88M | 124.45%267.79M |
| -Changes in the fair value of other assets | 599.86%896.43M | 301.89%1.29B | 255.64%804.82M | -39.84%140.92M | -56.71%128.09M | -337.93%-637.15M | -415.26%-517.12M | 123.12%234.23M | 124.64%295.88M | 124.45%267.79M |
| Impairment and provision | 40.38%-433.47M | 68.86%-140.69M | 30.74%-121.47M | 20.95%-897.51M | -0.02%-727.12M | -0.27%-451.82M | 31.31%-175.39M | -142.29%-1.14B | -49.04%-726.99M | -121.16%-450.61M |
| -Other impairment is provision | 40.38%-433.47M | 68.86%-140.69M | 30.74%-121.47M | 20.95%-897.51M | -0.02%-727.12M | -0.27%-451.82M | 31.31%-175.39M | -142.29%-1.14B | -49.04%-726.99M | -121.16%-450.61M |
| Special items of operating profit | -52.76%2.13B | 10.07%2.23B | 1.88%1.42B | -43.39%3.57B | 6.59%4.51B | -28.81%2.02B | 4.26%1.39B | 51.63%6.32B | 18.26%4.23B | 49.74%2.84B |
| Operating profit | -129.74%-8.97B | -34.46%10.79B | 102.83%10.57B | 174.65%36.84B | 158.65%30.15B | 98.42%16.47B | 45.28%5.21B | 330.49%13.42B | 329.07%11.66B | 236.56%8.3B |
| Financing income | 61.42%1.51B | 60.14%999.67M | 75.64%491.36M | 57.73%1.29B | 55.49%937.34M | 55.44%624.25M | 51.70%279.76M | 24.48%818.99M | 18.08%602.83M | 33.53%401.61M |
| Financing cost | -51.84%-1.32B | -49.09%-905.33M | -47.62%-475.12M | 6.18%-1.34B | 17.91%-868.89M | 14.17%-607.24M | 8.94%-321.86M | 12.50%-1.43B | 13.50%-1.06B | 5.53%-707.48M |
| Special items of earning before tax | -86.51%117.22M | -83.57%107.68M | -94.13%18.45M | -2.22%1.19B | 71.39%869.22M | 802.17%655.4M | 731.44%314.2M | 3,282.76%1.21B | 285.03%507.17M | 120.54%72.65M |
| Earning before tax | -127.84%-8.66B | -35.85%10.99B | 93.39%10.6B | 170.90%37.99B | 165.52%31.09B | 112.49%17.14B | 62.80%5.48B | 307.56%14.02B | 306.49%11.71B | 217.25%8.07B |
| Tax | 129.68%446.05M | -37.12%-572.29M | -383.48%-543.92M | -1,223.17%-2.18B | -2,094.66%-1.5B | -2,170.46%-417.38M | -1,237.56%-112.5M | -334.40%-164.54M | -199.98%-68.48M | -130.49%-18.38M |
| After-tax profit from continuing operations | -127.75%-8.21B | -37.67%10.42B | 87.31%10.06B | 158.41%35.81B | 154.17%29.59B | 107.79%16.72B | 59.86%5.37B | 307.28%13.86B | 307.80%11.64B | 218.02%8.05B |
| Earning after tax | -127.75%-8.21B | -37.67%10.42B | 87.31%10.06B | 158.41%35.81B | 154.17%29.59B | 107.79%16.72B | 59.86%5.37B | 307.28%13.86B | 307.80%11.64B | 218.02%8.05B |
| Minority profit | -19.32%898K | -38.00%532K | -87.98%53K | -23.95%1.14M | -8.62%1.11M | -14.80%858K | 70.93%441K | 90.98%1.5M | 55.36%1.22M | 142.65%1.01M |
| Profit attributable to shareholders | -127.75%-8.21B | -37.67%10.42B | 87.33%10.06B | 158.43%35.81B | 154.19%29.59B | 107.81%16.72B | 59.86%5.37B | 307.23%13.86B | 307.75%11.64B | 218.00%8.05B |
| Basic earnings per share | -36.30%1.72 | 162.33%5.85 | 107.69%2.7 | 304.59%2.23 | 217.12%1.3 | |||||
| Diluted earnings per share | -37.60%1.61 | 168.25%5.66 | 113.22%2.58 | 293.58%2.11 | 209.01%1.21 | |||||
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | PricewaterhouseCoopers | -- | -- | -- | PricewaterhouseCoopers | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.